Compare GXAI & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | HKPD |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | 27 |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.2M |
| IPO Year | 2022 | N/A |
| Metric | GXAI | HKPD |
|---|---|---|
| Price | $0.85 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 244.0K | 208.9K |
| Earning Date | 05-14-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $271.23 | N/A |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.73 | $0.31 |
| 52 Week High | $2.96 | $2.58 |
| Indicator | GXAI | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 49.71 |
| Support Level | $0.73 | $0.32 |
| Resistance Level | $1.32 | $0.47 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 30.51 | 71.48 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.